Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 4/20 | 0.74 |
| ▸ | NPY2R | P49146 | 4/20 | 0.74 |
| ▸ | NPY4R | P50391 | 4/20 | 0.74 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.65 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.65 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.65 |
| ▸ | KISS1R | Q969F8 | 7/20 | 0.60 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.57 |
| ▸ | MC4R | P32245 | 3/20 | 0.57 |
| ▸ | MC1R | Q01726 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390038 | 0.93 | NPY1R (0.67) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29738308 | 0.93 | ERAP2 (0.73) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29924773 | 0.93 | ERAP2 (0.73) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29426680 | 0.91 | NPY1R (0.68) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29805135 | 0.90 | NPY1R (0.79) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL30797506 | 0.90 | NPY1R (0.79) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29402231 | 0.89 | GHSR (0.69) | NPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30887362 | 0.88 | GHSR (0.67) | NPY1RNPY2RNPY4R | |
| SCHEMBL29559198 | 0.88 | NPY1R (0.65) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL30165601 | 0.88 | ERAP2 (0.63) | NPY1RNPY2RNPY4RERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681776-A2 | ANTIMICROBIAL THERAPY | The Regents of the University of California (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4656245-A1 | HISTIDINE-BASED UNNATURAL AMINO ACID, ITS PRODUCTION AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-12-03 | — | — | EP | claimed |
| US-20250361272-A1 | HISTIDINE-BASED UNNATURAL AMINO ACID, ITS PRODUCTION AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-11-27 | — | — | US | claimed |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | UNIV CALIFORNIA (US) | 2025-11-06 | — | — | US | claimed |
| CN-119744866-A | Application of glycine in resisting low-temperature stress of apple trees | 沈阳农业大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119623017-A | Optimal design method based on double-motor mode switching rule | 吉林大学 | 2025-03-14 | — | — | CN | claimed |
| CN-112183948-B | Commercial and trade enterprise value-added tax invoice virtual issuing risk assessment method based on entry and sales item comparison | 神州数码信息系统有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20230110869-A1 | Expressing Multiple Genes from a Single Transcript in Algae and Plants | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | claimed |
| CN-115715781-A | Antimicrobial therapy | 加利福尼亚大学董事会 | 2023-02-28 | — | — | CN | claimed |
| CN-115189354-A | Through type cophase power supply system structure of electrified railway | 西南交通大学 | 2022-10-14 | — | — | CN | claimed |
| CN-114573669-A | Application of protein Ghd7 in regulation and control of low nitrogen resistance of plants | 中国科学院遗传与发育生物学研究所 | 2022-06-03 | — | — | CN | claimed |
| WO-2022026341-A1 | EXPRESSING MULTIPLE GENES FROM A SINGLE TRANSCRIPT IN ALGAE AND PLANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-03 | — | — | WO | claimed |
| US-20260117201-A1 | Polynucleotides for use in AAV production | ENCODED THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4719327-A1 | TOPICAL FORMULATION COMPRISING DELIQUESCENT SUBSTANCE | L'OREAL (FR) | 2026-04-08 | — | — | EP | disclosed |
| US-12596649-B2 | Memory access device and operating method thereof | REBELLIONS INC. (KR) | 2026-04-07 | — | — | US | disclosed |
| US-20260093537-A1 | TECHNIQUES FOR RESOURCE ALLOCATION AND MANAGEMENT | DELL PRODUCTS L.P. (US) | 2026-04-02 | — | — | US | disclosed |
| US-20220064656-A1 | GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF | GENENEER LTD. (IL) | 2022-03-03 | — | — | US | disclosed |
| EP-3953456-A1 | METHODS FOR MODULATING MACROPHAGE ACTIVITY | Riptide Bioscience, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022026341-A1 | EXPRESSING MULTIPLE GENES FROM A SINGLE TRANSCRIPT IN ALGAE AND PLANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220038284-A1 | Testing and Other Data Communicated Using Trust Models In Decentralized and Distributed Systems | SAFELISHARE, INC. | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117201-A1 | Polynucleotides for use in AAV production | UPF1, PHAX, ANKRD52 | NPY1R 1877/4885NPY2R 2306/4885NPY4R 2310/4885 |
| US-20260093537-A1 | TECHNIQUES FOR RESOURCE ALLOCATION AND MANAGEMENT | CLPP, DSTN, VSIR | NPY1R 1553/4885NPY2R 1483/4885NPY4R 684/4885 |
| US-20250361272-A1 | HISTIDINE-BASED UNNATURAL AMINO ACID, ITS PRODUCTION AND USE | H1-0, BCAT1, H1-2 | NPY1R 108/4885NPY2R 438/4885NPY4R 408/4885 |
| US-12596649-B2 | Memory access device and operating method thereof | L1CAM, MRE11, CA1 | NPY1R 4276/4885NPY2R 3754/4885NPY4R 4405/4885 |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | LCT, HM13, ITCH | NPY1R 2184/4885NPY2R 2611/4885NPY4R 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.